ArticleCancer biology & therapy2019
LOX and ACSL5 as potential relapse markers for pancreatic cancer patients.
Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Deuterium modification of tyrosine kinase inhibitors contributes to reversing ferroptosis resistance through upregulation of aldehyde oxidase 1 in hepatocellular carcinoma.Acta pharmaceutica Sinica. B · 2026Article
- Transcriptome analysis of orbital tissue in thyroid eye disease uncovers key pathogenic mediators.Scientific reports · 2025Article
- A new combined prognostic model involvingTranslational cancer research · 2025Article
- ACSL5 regulated acetyl-CoA to promote bladder cancer cellular senescence via 53BP1 acetylation.Oncogene · 2025Article
- Systematic Characterisation and Analysis of Lysyl Oxidase Family Members as Drivers of Tumour Progression and Multiple Drug Resistance.Journal of cellular and molecular medicine · 2025Article
- Bioinformatics insights into ACSL1 and ACSL5: prognostic and immune roles in low-grade glioma.BMC cancer · 2025Article
- Dysregulation of genes involved in the long-chain fatty acid transport in pancreatic ductal adenocarcinoma.World journal of gastrointestinal oncology · 2025Article
- A bioprinted sea-and-island multicellular model for dissecting human pancreatic tumor-stroma reciprocity and adaptive metabolism.Biomaterials · 2024Article
- Deciphering fatty acid biosynthesis-driven molecular subtypes in pancreatic ductal adenocarcinoma with prognostic insights.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Obesity enhances the response to neoadjuvant anti-PD1 therapy in oral tongue squamous cell carcinoma.Cancer medicine · 2024Article
- Comprehensive investigation of tumor immune microenvironment and prognostic biomarkers in osteosarcoma through integrated bulk and single-cell transcriptomic analysis.Frontiers in immunology · 2024Article
- A Novel Peroxisome-Related Gene Signature Predicts Breast Cancer Prognosis and Correlates with T Cell Suppression.Breast cancer (Dove Medical Press) · 2024Article
- Article
- Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma.Oncogene · 2023Article
- Increased expression of GIPC2 in colon adenocarcinoma is associated with a favorable prognosis and high levels of immune cell infiltration.Oncology reports · 2023Article
- Revealing the impact of TOX3 on osteoarthritis: insights from bioinformatics.Frontiers in medicine · 2023Article
- Article
- Potential biomarkers for the early detection of bone metastases.Frontiers in oncology · 2023Review
- Construction and validation of a fatty acid metabolism risk signature for predicting prognosis in acute myeloid leukemia.BMC genomic data · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the most malignant diseases and has a poor prognosis. The screening and validation of biomarkers with predictive value for prognosis and treatment efficacy are important. To identify potential prognostic markers of pancreatic cancer patients, we conducted a study that included 99 pancreatic cancer patients. Three patients with PFS>18 months were enrolled in the treat group, and three patients with PFS<12 months were enrolled in the control group. Differentially expressed genes (DEGs) between these two groups were analyzed by whole-genome expression microarray. A total of 178 DEGs were identified, including 110 up-regulated and 68 down-regulated genes. Next, 24 candidate genes were selected for validation by qPCR based on fold change and previous studies. The results showed that the mRNA levels of four candidate genes, including ACSL5, SLC44A4, LOX, and TOX3, were correlated with PFS. Immunohistochemical staining was performed to validate the protein expression levels of these four markers. The results showed that patients with LOX
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.